Published in Clin Cancer Res on March 07, 2017
CDK4/6 inhibition triggers anti-tumour immunity. Nature (2017) 0.99
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance? Oncoscience (2017) 0.75
The transcriptome of CDK4/6 inhibition. Aging (Albany NY) (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Cancer cell cycles. Science (1996) 21.29
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res (2015) 14.81
Using GOstats to test gene lists for GO term association. Bioinformatics (2006) 12.58
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Distinct roles for cyclin-dependent kinases in cell cycle control. Science (1993) 8.13
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
Retinoblastoma protein switches the E2F site from positive to negative element. Nature (1992) 5.47
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res (2010) 4.61
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21
Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene (1996) 2.96
Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med (2016) 2.37
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell (2014) 2.09
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov (2011) 1.76
Progesterone inhibits estrogen-induced cyclin D1 and cdk4 nuclear translocation, cyclin E- and cyclin A-cdk2 kinase activation, and cell proliferation in uterine epithelial cells in mice. Mol Cell Biol (1999) 1.69
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics (2007) 1.60
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35
Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res (2007) 1.31
Progesterone, in addition to estrogen, induces cyclin D1 expression in the murine mammary epithelial cell, in vivo. Endocrinology (1997) 1.26
Genome Modeling System: A Knowledge Management Platform for Genomics. PLoS Comput Biol (2015) 1.21
Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer (2015) 1.21
Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology (1997) 0.97
Regulation of the cyclin D3 promoter by E2F1. J Biol Chem (2003) 0.97
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clin Cancer Res (2015) 0.96
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J (2010) 0.90
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun (2016) 0.88
Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Mol Reprod Dev (1997) 0.88
E2F1-mediated upregulation of p19INK4d determines its periodic expression during cell cycle and regulates cellular proliferation. PLoS One (2011) 0.87
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res (2016) 0.86
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids (2011) 0.84
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol (2016) 0.83
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res (2016) 0.83
GenVisR: Genomic Visualizations in R. Bioinformatics (2016) 0.83
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol (2017) 0.83
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. Breast (2016) 0.77
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer. Adv Exp Med Biol (2016) 0.76
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nat Commun (2016) 0.75
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clin Cancer Res (2015) 0.96
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clin Cancer Res (2016) 0.85
Scoliosis and vertebral anomalies: additional abnormal phenotypes associated with chromosome 16p11.2 rearrangement. Am J Med Genet A (2014) 0.82
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer. Clin Cancer Res (2017) 0.76
Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer. Cancer Med (2015) 0.76
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clin Cancer Res (2020) 0.75
A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. Clin Cancer Res (2017) 0.75